Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510897 · ClinicalTrials.gov registry record · Phase 3
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
A Phase 3 study, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,043
- Enrollment target
NCT03510897 is a Phase 3 study that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 1,043 participants.
The verdict
NCT03510897, a Phase 3 study, was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,043 participants
- Enrollment target
Study Summary
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
Interventions
- DRUG Placebo
- DRUG teprasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,043 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2021-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03510897
The ClinicalTrials.gov registry entry for NCT03510897 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,043 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03510897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03510897 about?
NCT03510897 is a clinical study titled "QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery". This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
What is the current status of trial NCT03510897?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,043 participants. The study started on 2018-06-29. Estimated completion is 2021-04-12.
What interventions are being tested in trial NCT03510897?
The interventions under investigation include: Placebo (DRUG), teprasiran (DRUG).
Who is sponsoring clinical trial NCT03510897?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.